FINWIRES · TerminalLIVE
FINWIRES

Update: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

By

(Updates with layoff plan in the sixth paragraph and recent stock price move in the last paragraph.)

BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.

Analysts polled by FactSet expected a loss of 1.27 euros.

Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 billion euros a year earlier.

Analysts surveyed by FactSet expected 164.6 million euros.

For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts expect 2.22 billion euros.

The company said it plans to exit operations at manufacturing sites in Idar-Oberstein, Marburg and Singapore, as well as CureVac's sites, affecting up to about 1,860 positions. The moves are expected to be completed by 2027 and deliver about 500 million euros in annual cost savings by 2029.

BioNTech shares were down 2.4% in Tuesday trading.

Price: $96.96, Change: $-2.39, Percent Change: -2.41%

Related Articles

Wire

IAC Q1 Loss Narrows, Revenue Falls; Shares Drop After Hours

IAC (IAC) reported a Q1 loss late Monday of $0.94 per diluted share, narrowing from the loss of $2.64 a year earlier.Analysts polled by FactSet expected a loss of $0.37.Revenue in the three months ended March 31 fell to $422.9 million from $481.7 million a year earlier.Analysts surveyed by FactSet expected $520.3 million.IAC shares fell 8.6% in after-hours trading.

$IAC
Wire

Vornado Realty Trust Q1 Non-GAAP FFO, Revenue Fall; Shares Drop After Hours

Vornado Realty Trust (VNO) reported Q1 non-GAAP funds from operations late Monday of $0.52 per diluted share, down from $0.63 a year earlier.Analysts polled by FactSet expected $0.51.Revenue in the three months ended March 31 fell to $459.1 million from $461.6 million a year earlier.Analysts surveyed by FactSet expected $431.7 million.Vornado shares fell 3% in after-hours trading.

$VNO
Wire

GeneDx Q1 Swings to Adjusted Loss, Revenue Rises; 2026 Revenue Guidance Lowered; Shares Fall

GeneDx (WGS) reported Monday Q1 adjusted loss of $0.28 per diluted share, swinging from an adjusted earnings of $0.31 a year earlier.Analysts polled by FactSet expected loss of $0.02.Revenue for the quarter ended March 31 was $102.3 million, up from $87.1 million a year earlier.Analysts surveyed by FactSet expected $112.5 million.For Q2, the company expects revenue of $110 million to $112 million. Analysts expect $130.3 million.The company now expects 2026 revenue of $475 million to $490 million, down from $540 million to $555 million expected earlier. Analysts expect $550.0 million.Shares of the company were down over 45% during after-hours activity.

$WGS